Saladax Biomedical Announces Exclusive Distribution Agreement in Canada
Saladax Biomedical, Inc. (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics Inc. (HLS) (TSX: HLS) to distribute five MyCare Psychiatry Laboratory Assays, used to measure the six most prescribed antipsychotic medications in Canada.
The MyCare Psychiatry Laboratory Assays are crucial diagnostic tools for monitoring a patient's antipsychotic drug blood levels. These medications can have adverse effects if the drug level is too high, and if the level is too low, the patient's condition may not be adequately treated.
Current methods for determining drug levels are not fast enough, limiting their clinical utility. Providing clinicians with quick antipsychotic drug tests will increase patient access to this important testing and assist healthcare providers in managing their patient's treatment. Traditionally, these tests were only available and performed by centralized reference laboratories using specialized instruments. As a result, by the time healthcare providers receive the results, the clinical utility of the tests is significantly reduced.
MyCare Laboratory Assays can be run on existing automated analyzers already present in most hospital laboratories, expanding access for patients and providing results quickly enough to offer clinical benefits.
Health Canada recently approved the MyCare Psychiatry Laboratory Assays to measure blood drug concentrations for clozapine, risperidone, paliperidone, aripiprazole, olanzapine, and quetiapine.
"The availability of our assays on a routine basis means that clinicians, for the first time, will have a useful diagnostic tool to aid in the management and optimization of their patient's treatment," said the President and CEO, and Founder of Saladax. "By advancing our partnership with HLS, we are confident that Canadians will now have increased access to this essential testing, which will assist clinicians in managing their patient’s treatment."
Source: Saladax Biomedical, Inc.
No comments:
Post a Comment